We can't find evidence that holds up here. Proponents are reasoning from mechanism or analogy rather than direct human data, and the most credible skeptics raise objections we can't dismiss.
Compounded rapamycin may have essentially no bioavailability if it's not in an inter capsule so this is this actually goes back to the reason why the ITP took 20 months to start their experiment is rapy is unstable at gastric pH and so if compounded rapy is not in an inic coded capsule you're essentially going to get zero bio bioavailability
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
The "high risk" framing here is the right call. I've had three patients ask about rapa this month and none of them grasped the immunosuppression tradeoff until I walked them through it.
The PEARL trial framing in the dossier is the clearest writeup I've seen for a non-specialist. Worth linking from the AMA pages too.
I'm on 6mg/week, year two. Tracking IL-6, fasting glucose, lipids. Happy to share the spreadsheet if Whalespan wants longitudinal user data.
The dosing variance across the advocate camp is staggering. 3mg, 5mg, 8mg, biweekly, weekly… brief is right that "monitor or specialist only" is the responsible read.
but I would caution people against using any compounded formulations here yes they'll make it a lot cheaper but it you have virtually no guarantee of the Purity uh or the concentration and we're already taking a huge leap of faith with this so unless you know and I we just will have a podcast that covers the the ins and outs of compounding pharmacies I'm not here to suggest they're all bad but but you you absolutely want to be able to make sure you have FDA certificates for what you're using and just kind of be careful with with the with the quality control
Rapamycin extends median and maximum lifespan in mice across multiple lab strains and dosing protocols.
Rapamycin will extend human lifespan by 5+ years at standard weekly dosing.
Weekly rapamycin dosing in healthy adults shows favorable safety and immune markers in early observational data.
Chronic low-dose rapamycin imposes an immune trade-off that outweighs the longevity hypothesis for most healthy adults.
mTORC1 inhibition is the mechanistic backbone for rapamycin's healthspan effects in mammals.
The PEARL trial showed an acceptable 48-week safety profile in healthy adults on weekly rapamycin.